Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 34422: A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma

99 years and younger
All genders
Phase 2 trial studying the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that relapsed or does not respond to treatment (refractory). We would like to rely on Advarra as the IRB of record for this study.
Learn More

UPCC 27423 V-RULES: Vyxeos Real-world US Long-term Effectiveness and Safety Study

99 years and younger
All genders
This is a retrospective, non-interventional, multi-center, single-arm, observational study of patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who have been treated with Vyxeos in real world clinical practice and managed as per the healthcare providers discretion. The study will collect pseudonymized patient …
Learn More

UPCC 23222: A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas

99 years and younger
All genders
This is a multi-center, open-label, single arm Phase 1b/2a study of gemcitabine and nab-paclitaxel in combination with VS-6766 and defactinib in patients with previously untreated metastatic PDAC. We would like to rely on Advarra as the IRB of record for this study.
Learn More

UPCC 16923 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

99 years and younger
All genders
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors.
Learn More

UPCC 03023: A Phase 1, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis

99 years and younger
All genders
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints)
Learn More

UPCC 21923: A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

99 years and younger
All genders
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2.2.1 (Primary Endpoints) Please see the Protocol, Section 2.2.2 (Secondary Endpoints)
Learn More

UPCC 15123: Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant

99 years and younger
All genders
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer …
Learn More

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

99 years and younger
All genders
This phase 3 trial studies how well active surveillance help doctors to monitor subjects with low-risk germ cell tumors for recurrence after their tumor is removed. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells. The trial studies whether carboplatin or cisplatin is the …
Learn More

UPCC 25423 A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

99 years and younger
All genders
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). We would like to rely on WCG IRB as …
Learn More

A Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas (CPI 0209)

18-99 years
Female
Phase 1/2
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
Learn More
61 - 70 of 206